Combination chemotherapy for metastatic colorectal cancer

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements. Through the biochemical modulation of 5-fluorouracil (5-FU) with folinic acid (FA), the use of infusional rather than bolus regimens and the combination of 5-FU/FA with other active agents (notably irinotecan), first-line response rates (RRs) of 40% can be achieved, with patients surviving up to 17...

متن کامل

Intrahepatic Chemotherapy 2 for Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the fourth most common malignancy in the United States (1). Approximately 130,000 new patients will be diagnosed with this cancer in 1999. It is the second leading cause of cancer death, with 55,000 patients expected to die of it. Most patients die of metastatic disease. The vast majority of them have liver as the dominant site of metastases (2). Approximately 30% of ...

متن کامل

New Option for Metastatic Colorectal Cancer: Oxaliplatin and Novel Oral S-1 Combination Chemotherapy

The combination of oxaliplatin or irinotecan with bolus and infusional fluorouracil (FU) and folinic acid (FA) is considered the standard regimen for the first-line treatment of metastatic colorectal cancer [1–4]. However, this regimen is inconvenient owing to its requirement for continuous infusion of FU via vascular access. To overcome this drawback, oral fluoropyrimidines such as capecitabin...

متن کامل

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer based on the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technolog...

متن کامل

Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer.

Toxicities commonly associated with antiangiogenic agents include hypertension, proteinuria, wound-healing complications, bleeding or hemorrhage, thromboembolic events, hypersensitivity reactions, and gastrointestinal perforation; however, toxicities most often attributed to chemotherapy include nausea, vomiting, diarrhea, constipation, fatigue, neuropathy, mucositis, hand-foot syndrome, hypers...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Arhiv za onkologiju

سال: 2003

ISSN: 0354-7310,1450-9520

DOI: 10.2298/aoo0303155k